The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary embolism - Venous thrombosis/thromboembolism
Publications
Intravenous Immunoglobulin-Induced Pulmonary Embolism: It Is Time to Act!
American journal of therapeutics 2016 Jul-Aug;23;e1074-7 — 2016 Jul-Aug — e1074-7
Severe thromboembolic complications associated with the administration of intravenous immunoglobulins.
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2012 May-Jun;36;166-7 — 2012 May-Jun — 166-7
Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study.
Journal of the neurological sciences 2011 Sep 15;308;124-7 — 2011 Sep 15 — 124-7
Thromboembolic complications of intravenous immunoglobulin (IVIG) in an immunocompromised patient with Chronic Lymphocytic Leukemia: a case report.
Cases journal 2009 Nov 23;2;9078 — 2009 Nov 23 — 9078
Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris.
Cutis 2004 Jun;73;403-6 — 2004 Jun — 403-6
Pulmonary embolism after intravenous immunoglobulin.
Journal of the Royal Society of Medicine 2001 Apr;94;187-8 — 2001 Apr — 187-8